ChloroquineV1, PascalFrancis, Curation, bibRecord, 000052

Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry

Identifieur interne : 000052 ( PascalFrancis/Curation ); précédent : 000051; suivant : 000053

Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry

Auteurs : Ling-Zhi Wang [Singapour] ; Michelle Yi-Xiu Lim [Singapour] ; Tan-Min Chin [Singapour] ; Win-Lwin Thuya [Singapour] ; Pei-Ling Nye [Singapour] ; Andrea Wong [Singapour] ; Sui-Yung Chan [Singapour] ; Boon-Cher Goh [Singapour] ; Paul C. Ho [Singapour]

Source :

Journal of chromatography. B [ 1570-0232 ] ; 2011.

RBID : Pascal:11-0332687

Descripteurs français

Pascal (Inist)
- Analyse quantitative, Détermination, Géfitinib, Métabolite, Homme, Liquide biologique, Plasma sanguin, Chromatographie HPLC, Spectrométrie masse tandem, Anticancéreux, LC MS MS.
Wicri :
- topic : Analyse quantitative, Homme.

English descriptors

KwdEn :
- Antineoplastic agent, Biological fluid, Blood plasma, Determination, Gefitinib, HPLC chromatography, Human, Mass spectrometry MS/MS, Metabolite, Quantitative analysis.

Abstract

A novel, rapid and specific liquid chromatography-tandem mass spectrometric (LC-MS/MS) method was developed and validated for the simultaneous quantification of gefitinib and its predominant metabolite, O-desmethyl gefitinib in human plasma. Chromatographic separation of analytes was achieved on an Alltima C18 analytical HPLC column (150mm x 2.1 mm, 5 μm) using an isocratic elution mode with a mobile phase comprised acetonitrile and 0.1% formic acid in water (30:70, v/v). The flow rate was 300 μL/min. The chromatographic run time was 3 min. The column effluents were detected by API 4000 triple quadrupole mass spectrometer using electrospray ionization (ESI) in positive mode. Linearity was demonstrated in the range of 5-1000 ng/mL for gefitinib and 5-500 ng/mL for O-desmethyl gefitinib. The intra- and inter-day precisions for gefitinib and O-desmethyl gefitinib were ≤10.8% and the accuracies ranged from 89.7 to 104.7% for gefitinib and 100.4 to 106.0% for O-desmethyl gefitinib. This method was used as a bioanalytical tool in a phase I clinical trial to investigate the possible effect of hydroxychloroquine on the pharmacokinetics of gefitinib. The results of this study enabled clinicians to ascertain the safety of the combination therapy of hydroxychloroquine and gefitinib in patients with advanced (Stage IIIB-IV) non-small cell lung cancer (NSCLC).

A01	`01`	`1`		`@0 1570-0232`
A03		`1`		`@0 J. chromatogr., B`
A05				`@2 879`
A06				`@2 22`
A08	`01`	`1`	`ENG`	`@1 Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry`
A11	`01`	`1`		`@1 WANG (Ling-Zhi)`
A11	`02`	`1`		`@1 YI-XIU LIM (Michelle)`
A11	`03`	`1`		`@1 CHIN (Tan-Min)`
A11	`04`	`1`		`@1 THUYA (Win-Lwin)`
A11	`05`	`1`		`@1 NYE (Pei-Ling)`
A11	`06`	`1`		`@1 WONG (Andrea)`
A11	`07`	`1`		`@1 CHAN (Sui-Yung)`
A11	`08`	`1`		`@1 GOH (Boon-Cher)`
A11	`09`	`1`		`@1 HO (Paul C.)`
A14	`01`			`@1 Cancer Science Institute of Singapore, National University of Singapore @3 SGP @Z 1 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 8 aut.`
A14	`02`			`@1 Department of Pharmacy, National University of Singapore @3 SGP @Z 2 aut. @Z 7 aut. @Z 9 aut.`
A14	`03`			`@1 Department of Haematology & Oncology, National University Health System @3 SGP @Z 3 aut. @Z 6 aut. @Z 8 aut.`
A20				`@1 2155-2161`
A21				`@1 2011`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 8577B @5 354000190464250200`
A44				`@0 0000 @1 © 2011 INIST-CNRS. All rights reserved.`
A45				`@0 18 ref.`
A47	`01`	`1`		`@0 11-0332687`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of chromatography. B`
A66	`01`			`@0 NLD`
C01	`01`		`ENG`	@0 A novel, rapid and specific liquid chromatography-tandem mass spectrometric (LC-MS/MS) method was developed and validated for the simultaneous quantification of gefitinib and its predominant metabolite, O-desmethyl gefitinib in human plasma. Chromatographic separation of analytes was achieved on an Alltima C18 analytical HPLC column (150mm x 2.1 mm, 5 μm) using an isocratic elution mode with a mobile phase comprised acetonitrile and 0.1% formic acid in water (30:70, v/v). The flow rate was 300 μL/min. The chromatographic run time was 3 min. The column effluents were detected by API 4000 triple quadrupole mass spectrometer using electrospray ionization (ESI) in positive mode. Linearity was demonstrated in the range of 5-1000 ng/mL for gefitinib and 5-500 ng/mL for O-desmethyl gefitinib. The intra- and inter-day precisions for gefitinib and O-desmethyl gefitinib were ≤10.8% and the accuracies ranged from 89.7 to 104.7% for gefitinib and 100.4 to 106.0% for O-desmethyl gefitinib. This method was used as a bioanalytical tool in a phase I clinical trial to investigate the possible effect of hydroxychloroquine on the pharmacokinetics of gefitinib. The results of this study enabled clinicians to ascertain the safety of the combination therapy of hydroxychloroquine and gefitinib in patients with advanced (Stage IIIB-IV) non-small cell lung cancer (NSCLC).
C02	`01`	`X`		`@0 002B02A02`
C02	`02`	`X`		`@0 002A02`
C03	`01`	`X`	`FRE`	`@0 Analyse quantitative @5 01`
C03	`01`	`X`	`ENG`	`@0 Quantitative analysis @5 01`
C03	`01`	`X`	`SPA`	`@0 Análisis cuantitativo @5 01`
C03	`02`	`X`	`FRE`	`@0 Détermination @5 02`
C03	`02`	`X`	`ENG`	`@0 Determination @5 02`
C03	`02`	`X`	`SPA`	`@0 Determinación @5 02`
C03	`03`	`X`	`FRE`	`@0 Géfitinib @2 FR @5 03`
C03	`03`	`X`	`ENG`	`@0 Gefitinib @2 FR @5 03`
C03	`03`	`X`	`SPA`	`@0 Gefitinib @2 FR @5 03`
C03	`04`	`X`	`FRE`	`@0 Métabolite @5 04`
C03	`04`	`X`	`ENG`	`@0 Metabolite @5 04`
C03	`04`	`X`	`SPA`	`@0 Metabolito @5 04`
C03	`05`	`X`	`FRE`	`@0 Homme @5 05`
C03	`05`	`X`	`ENG`	`@0 Human @5 05`
C03	`05`	`X`	`SPA`	`@0 Hombre @5 05`
C03	`06`	`X`	`FRE`	`@0 Liquide biologique @5 06`
C03	`06`	`X`	`ENG`	`@0 Biological fluid @5 06`
C03	`06`	`X`	`SPA`	`@0 Líquido biológico @5 06`
C03	`07`	`X`	`FRE`	`@0 Plasma sanguin @5 07`
C03	`07`	`X`	`ENG`	`@0 Blood plasma @5 07`
C03	`07`	`X`	`SPA`	`@0 Plasma sanguíneo @5 07`
C03	`08`	`X`	`FRE`	`@0 Chromatographie HPLC @5 08`
C03	`08`	`X`	`ENG`	`@0 HPLC chromatography @5 08`
C03	`08`	`X`	`SPA`	`@0 Cromatografía HPLC @5 08`
C03	`09`	`X`	`FRE`	`@0 Spectrométrie masse tandem @5 09`
C03	`09`	`X`	`ENG`	`@0 Mass spectrometry MS/MS @5 09`
C03	`09`	`X`	`SPA`	`@0 Espectrometría masa en tándem @5 09`
C03	`10`	`X`	`FRE`	`@0 Anticancéreux @5 23`
C03	`10`	`X`	`ENG`	`@0 Antineoplastic agent @5 23`
C03	`10`	`X`	`SPA`	`@0 Anticanceroso @5 23`
C03	`11`	`X`	`FRE`	`@0 LC MS MS @4 INC @5 86`
C07	`01`	`X`	`FRE`	`@0 Inhibiteur enzyme @5 37`
C07	`01`	`X`	`ENG`	`@0 Enzyme inhibitor @5 37`
C07	`01`	`X`	`SPA`	`@0 Inhibidor enzima @5 37`
C07	`02`	`X`	`FRE`	`@0 Dérivé de la quinazoline @2 FR @5 38`
C07	`02`	`X`	`ENG`	`@0 Quinazoline derivatives @2 FR @5 38`
C07	`03`	`X`	`FRE`	`@0 Protein-tyrosine kinase @2 FE @5 39`
C07	`03`	`X`	`ENG`	`@0 Protein-tyrosine kinase @2 FE @5 39`
C07	`03`	`X`	`SPA`	`@0 Protein-tyrosine kinase @2 FE @5 39`
C07	`04`	`X`	`FRE`	`@0 Transferases @2 FE`
C07	`04`	`X`	`ENG`	`@0 Transferases @2 FE`
C07	`04`	`X`	`SPA`	`@0 Transferases @2 FE`
C07	`05`	`X`	`FRE`	`@0 Enzyme @2 FE`
C07	`05`	`X`	`ENG`	`@0 Enzyme @2 FE`
C07	`05`	`X`	`SPA`	`@0 Enzima @2 FE`
C07	`06`	`X`	`FRE`	`@0 Inhibiteur de la tyrosine kinase @5 40`
C07	`06`	`X`	`ENG`	`@0 Tyrosine kinase inhibitor @5 40`
C07	`06`	`X`	`SPA`	`@0 Inhibidor tyrosine kinase @5 40`
C07	`07`	`X`	`FRE`	`@0 Anti-EGFR @4 INC @5 87`
N21				`@1 227`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000014

Links to Exploration step

Pascal:11-0332687

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry</title>
<author><name sortKey="Wang, Ling Zhi" sort="Wang, Ling Zhi" uniqKey="Wang L" first="Ling-Zhi" last="Wang">Ling-Zhi Wang</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cancer Science Institute of Singapore, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
</author>
<author><name sortKey="Yi Xiu Lim, Michelle" sort="Yi Xiu Lim, Michelle" uniqKey="Yi Xiu Lim M" first="Michelle" last="Yi-Xiu Lim">Michelle Yi-Xiu Lim</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Pharmacy, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
</author>
<author><name sortKey="Chin, Tan Min" sort="Chin, Tan Min" uniqKey="Chin T" first="Tan-Min" last="Chin">Tan-Min Chin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cancer Science Institute of Singapore, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Haematology & Oncology, National University Health System</s1>
<s3>SGP</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
</author>
<author><name sortKey="Thuya, Win Lwin" sort="Thuya, Win Lwin" uniqKey="Thuya W" first="Win-Lwin" last="Thuya">Win-Lwin Thuya</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cancer Science Institute of Singapore, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
</author>
<author><name sortKey="Nye, Pei Ling" sort="Nye, Pei Ling" uniqKey="Nye P" first="Pei-Ling" last="Nye">Pei-Ling Nye</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cancer Science Institute of Singapore, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
</author>
<author><name sortKey="Wong, Andrea" sort="Wong, Andrea" uniqKey="Wong A" first="Andrea" last="Wong">Andrea Wong</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Haematology & Oncology, National University Health System</s1>
<s3>SGP</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
</author>
<author><name sortKey="Chan, Sui Yung" sort="Chan, Sui Yung" uniqKey="Chan S" first="Sui-Yung" last="Chan">Sui-Yung Chan</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Pharmacy, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
</author>
<author><name sortKey="Goh, Boon Cher" sort="Goh, Boon Cher" uniqKey="Goh B" first="Boon-Cher" last="Goh">Boon-Cher Goh</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cancer Science Institute of Singapore, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Haematology & Oncology, National University Health System</s1>
<s3>SGP</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
</author>
<author><name sortKey="Ho, Paul C" sort="Ho, Paul C" uniqKey="Ho P" first="Paul C." last="Ho">Paul C. Ho</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Pharmacy, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0332687</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 11-0332687 INIST</idno>
<idno type="RBID">Pascal:11-0332687</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000014</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000052</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry</title>
<author><name sortKey="Wang, Ling Zhi" sort="Wang, Ling Zhi" uniqKey="Wang L" first="Ling-Zhi" last="Wang">Ling-Zhi Wang</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cancer Science Institute of Singapore, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
</author>
<author><name sortKey="Yi Xiu Lim, Michelle" sort="Yi Xiu Lim, Michelle" uniqKey="Yi Xiu Lim M" first="Michelle" last="Yi-Xiu Lim">Michelle Yi-Xiu Lim</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Pharmacy, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
</author>
<author><name sortKey="Chin, Tan Min" sort="Chin, Tan Min" uniqKey="Chin T" first="Tan-Min" last="Chin">Tan-Min Chin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cancer Science Institute of Singapore, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Haematology & Oncology, National University Health System</s1>
<s3>SGP</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
</author>
<author><name sortKey="Thuya, Win Lwin" sort="Thuya, Win Lwin" uniqKey="Thuya W" first="Win-Lwin" last="Thuya">Win-Lwin Thuya</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cancer Science Institute of Singapore, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
</author>
<author><name sortKey="Nye, Pei Ling" sort="Nye, Pei Ling" uniqKey="Nye P" first="Pei-Ling" last="Nye">Pei-Ling Nye</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cancer Science Institute of Singapore, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
</author>
<author><name sortKey="Wong, Andrea" sort="Wong, Andrea" uniqKey="Wong A" first="Andrea" last="Wong">Andrea Wong</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Haematology & Oncology, National University Health System</s1>
<s3>SGP</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
</author>
<author><name sortKey="Chan, Sui Yung" sort="Chan, Sui Yung" uniqKey="Chan S" first="Sui-Yung" last="Chan">Sui-Yung Chan</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Pharmacy, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
</author>
<author><name sortKey="Goh, Boon Cher" sort="Goh, Boon Cher" uniqKey="Goh B" first="Boon-Cher" last="Goh">Boon-Cher Goh</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cancer Science Institute of Singapore, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Haematology & Oncology, National University Health System</s1>
<s3>SGP</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
</author>
<author><name sortKey="Ho, Paul C" sort="Ho, Paul C" uniqKey="Ho P" first="Paul C." last="Ho">Paul C. Ho</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Pharmacy, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of chromatography. B</title>
<title level="j" type="abbreviated">J. chromatogr., B</title>
<idno type="ISSN">1570-0232</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of chromatography. B</title>
<title level="j" type="abbreviated">J. chromatogr., B</title>
<idno type="ISSN">1570-0232</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic agent</term>
<term>Biological fluid</term>
<term>Blood plasma</term>
<term>Determination</term>
<term>Gefitinib</term>
<term>HPLC chromatography</term>
<term>Human</term>
<term>Mass spectrometry MS/MS</term>
<term>Metabolite</term>
<term>Quantitative analysis</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Analyse quantitative</term>
<term>Détermination</term>
<term>Géfitinib</term>
<term>Métabolite</term>
<term>Homme</term>
<term>Liquide biologique</term>
<term>Plasma sanguin</term>
<term>Chromatographie HPLC</term>
<term>Spectrométrie masse tandem</term>
<term>Anticancéreux</term>
<term>LC MS MS</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Analyse quantitative</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A novel, rapid and specific liquid chromatography-tandem mass spectrometric (LC-MS/MS) method was developed and validated for the simultaneous quantification of gefitinib and its predominant metabolite, O-desmethyl gefitinib in human plasma. Chromatographic separation of analytes was achieved on an Alltima C18 analytical HPLC column (150mm x 2.1 mm, 5 μm) using an isocratic elution mode with a mobile phase comprised acetonitrile and 0.1% formic acid in water (30:70, v/v). The flow rate was 300 μL/min. The chromatographic run time was 3 min. The column effluents were detected by API 4000 triple quadrupole mass spectrometer using electrospray ionization (ESI) in positive mode. Linearity was demonstrated in the range of 5-1000 ng/mL for gefitinib and 5-500 ng/mL for O-desmethyl gefitinib. The intra- and inter-day precisions for gefitinib and O-desmethyl gefitinib were ≤10.8% and the accuracies ranged from 89.7 to 104.7% for gefitinib and 100.4 to 106.0% for O-desmethyl gefitinib. This method was used as a bioanalytical tool in a phase I clinical trial to investigate the possible effect of hydroxychloroquine on the pharmacokinetics of gefitinib. The results of this study enabled clinicians to ascertain the safety of the combination therapy of hydroxychloroquine and gefitinib in patients with advanced (Stage IIIB-IV) non-small cell lung cancer (NSCLC).</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1570-0232</s0>
</fA01>
<fA03 i2="1"><s0>J. chromatogr., B</s0>
</fA03>
<fA05><s2>879</s2>
</fA05>
<fA06><s2>22</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>WANG (Ling-Zhi)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>YI-XIU LIM (Michelle)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>CHIN (Tan-Min)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>THUYA (Win-Lwin)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>NYE (Pei-Ling)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>WONG (Andrea)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>CHAN (Sui-Yung)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>GOH (Boon-Cher)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>HO (Paul C.)</s1>
</fA11>
<fA14 i1="01"><s1>Cancer Science Institute of Singapore, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Pharmacy, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Haematology & Oncology, National University Health System</s1>
<s3>SGP</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA20><s1>2155-2161</s1>
</fA20>
<fA21><s1>2011</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>8577B</s2>
<s5>354000190464250200</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2011 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>18 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>11-0332687</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of chromatography. B</s0>
</fA64>
<fA66 i1="01"><s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>A novel, rapid and specific liquid chromatography-tandem mass spectrometric (LC-MS/MS) method was developed and validated for the simultaneous quantification of gefitinib and its predominant metabolite, O-desmethyl gefitinib in human plasma. Chromatographic separation of analytes was achieved on an Alltima C18 analytical HPLC column (150mm x 2.1 mm, 5 μm) using an isocratic elution mode with a mobile phase comprised acetonitrile and 0.1% formic acid in water (30:70, v/v). The flow rate was 300 μL/min. The chromatographic run time was 3 min. The column effluents were detected by API 4000 triple quadrupole mass spectrometer using electrospray ionization (ESI) in positive mode. Linearity was demonstrated in the range of 5-1000 ng/mL for gefitinib and 5-500 ng/mL for O-desmethyl gefitinib. The intra- and inter-day precisions for gefitinib and O-desmethyl gefitinib were ≤10.8% and the accuracies ranged from 89.7 to 104.7% for gefitinib and 100.4 to 106.0% for O-desmethyl gefitinib. This method was used as a bioanalytical tool in a phase I clinical trial to investigate the possible effect of hydroxychloroquine on the pharmacokinetics of gefitinib. The results of this study enabled clinicians to ascertain the safety of the combination therapy of hydroxychloroquine and gefitinib in patients with advanced (Stage IIIB-IV) non-small cell lung cancer (NSCLC).</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02A02</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002A02</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Analyse quantitative</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Quantitative analysis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Análisis cuantitativo</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Détermination</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Determination</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Determinación</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Géfitinib</s0>
<s2>FR</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Gefitinib</s0>
<s2>FR</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Gefitinib</s0>
<s2>FR</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Métabolite</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Metabolite</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Metabolito</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Homme</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Human</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Hombre</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Liquide biologique</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Biological fluid</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Líquido biológico</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Plasma sanguin</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Blood plasma</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Plasma sanguíneo</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Chromatographie HPLC</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>HPLC chromatography</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Cromatografía HPLC</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Spectrométrie masse tandem</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Mass spectrometry MS/MS</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Espectrometría masa en tándem</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Anticancéreux</s0>
<s5>23</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Antineoplastic agent</s0>
<s5>23</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Anticanceroso</s0>
<s5>23</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>LC MS MS</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Enzyme inhibitor</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Inhibidor enzima</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Dérivé de la quinazoline</s0>
<s2>FR</s2>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Quinazoline derivatives</s0>
<s2>FR</s2>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Protein-tyrosine kinase</s0>
<s2>FE</s2>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Protein-tyrosine kinase</s0>
<s2>FE</s2>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Protein-tyrosine kinase</s0>
<s2>FE</s2>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enzima</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Inhibiteur de la tyrosine kinase</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Tyrosine kinase inhibitor</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Inhibidor tyrosine kinase</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Anti-EGFR</s0>
<s4>INC</s4>
<s5>87</s5>
</fC07>
<fN21><s1>227</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000052 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000052 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:11-0332687
   |texte=   Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry
}}

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Chloroquine

Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry

Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri